Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs-Reference-Cited by-同舟云学术

Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs

Published:2013-01 Issue:1 Volume:24 Page:90-97
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Lombardi Giuseppe,Zustovich Fable,Farina Patrizia,Fiduccia Pasquale,Della Puppa Alessandro,Polo Valentina,Bertorelle Roberta,Gardiman Marina P.,Banzato Alberto,Ciccarino Pietro,Denaro Luca,Zagonel Vittorina

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference16 articles.

1. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.;Girardi;Oncologist,2010

2. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.;Scartozzi;Ann Oncol,2009

3. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.;Rini;J Natl Cancer Inst,2011

4. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity.;Mir;Oncologist,2011

5. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.;Wen;J Clin Oncol,2010

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced magnetic resonance imaging for glioblastoma: Oncology-radiology integration;Surgical Neurology International;2024-08-30

2. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma;ESMO Open;2024-04

3. Bevacizumab-Induced Hypertension in Glioblastoma Patients and Its Potential as a Modulator of Treatment Response;Hypertension;2023-08

4. Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?;Journal of Neurology;2023-02-22

5. Bevacizumab-Induced Hypertension as a Potential Physiological Clinical Biomarker for Improved Outcomes in Patients With Recurrent Glioblastoma Multiforme: A Systematic Review;Cureus;2022-09-17